Analysts at JPMorgan said this morning there’s a 50 per cent chance of a $5bn (£3.9bn) Zantac liability. Citi analyst Peter Verdult pegged the bill at between $2bn (£1.6bn) and $3bn (£2.4bn).

A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients. The three-day hearing ...

The FDA banned sales of ranitidine in 2020 over possible contamination with the suspected carcinogen N-nitrosodimethylamine (NDMA. Some manufacturers of the drug voluntarily suspended sales in ...

Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0544 ET – GSK’s $2.2 billion settlement to ...

CASE DETAILS: According to the filed complaint, defendants represented to investors that GSK removed Zantac from the market ... Class Action Services' Top 50 Report as one of the top securities ...

GSK launched Zantac in 1981 and it was first approved for sale in the US in 1983 as a prescription medication. It went on to become the world's best-selling drug, with annual sales in excess of $1bn.